MétaCan
Menu
Back to cohort

Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.

2016· article· en· W2492595798 on OpenAlexaffabout
Susan Dent, Olexiy Aseyev, Mark N. Levine, Kathleen I. Pritchard, Wendy R. Parulekar, Bingshu E. Chen, Patti O’Brien, Margot J. Burnell, Lois E. Shepherd

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsSaint John Regional HospitalSunnybrook Health Science CentreQueen's UniversityMcMaster UniversityUniversity of OttawaOttawa Hospital
Fundersnot available
KeywordsMedicineEpirubicinEjection fractionCardiotoxicityAnthracyclineHeart failureBreast cancerInternal medicineCyclophosphamideCardiologyRandomized controlled trialChemotherapyCancerSurgeryGastroenterology

Abstract

fetched live from OpenAlex

1016 Background: Anthracycline containing chemotherapy (An-CT) has led to improved clinical outcomes in women with early breast cancer (EBC); however cardiotoxicity (CTox) can occur acutely or years later. We report the incidence of CTox in women with EBC who participated in a large randomized phase III trial of 3 different An-CT regimens: cyclophosphamide (C) epirubicin (E) fluorouracil (F); dose dense EC followed by paclitaxel (T); and Adriamycin (A) and C followed by T. Methods: Women (≤60 years) were randomized to one of: Arm A – CEF (E: 60mg/m2 and F days 1 and 8 x 6); Arm B - EC/T (E: 120mg/m2 q2 weeks x 6 followed by T q 3 weeks x 4); Arm C - AC/T (A: 60mg/m2q3 weeks x 4 followed by T q3 weeks x 4). Left ventricular ejection fraction (LVEF) was measured at baseline by echocardiogram (ECHO) (19%) or MUGA (81%), then yearly x 5. CTox was defined as at least 10% decline in LVEF to below 50%. Left ventricular dysfunction (LVD) was defined as: mild (LVEF 40-50%); moderate/severe (LVEF < 40%). Congestive heart failure (CHF) was reported using the NCI Common Toxicity Criteria V.2.0 - cardiac LVF Grades 3 or 4. Results: 2104 women were accrued from 12/2000-04/2005. Mean change in LVEF (0 to 5 years): Arm A (63 to 57%;p<0.0001); Arm B: (63 to 59%: P< 0.0001); Arm C: (63 to 61%; p<0.0001). Conclusions: Pts treated with An-CT remain at risk of CTox up to 5 years after completing treatment. Higher rates of An-CT-induced LVD, CHF, and CTox were observed in the dose intense E treatment arms. While the use of An-CT in BC has been declining, large numbers of women previously treated with An-CT remain at risk for late CTox. Surveillance strategies are needed to guide appropriate identification and monitoring of this patient population. Clinical trial information: NCT00014222.Cardiotoxicity in patients with EBC at 5 years after treatment. Treatment Arm A (CEF) B (EC/T) C (AC/T) No. % No % No. % No. of women 701 33.3 701 33.3 702 33.3 Compliance with LVEF monitoring 575 82.0 589 84.0 548 78.0 Cardiotoxicity (p<0.0001) 38 6.6 24 4.1 7 1.3 Left Ventricular Dysfunction (LVD) Mild LVD (p<0.0001) 48 11.9 31 7.6 13 3. 4 Moderate/severe LVD(p=0.60) 4 0.9 2 0.5 2 0.6 Congestive Heart Failure (CHF) During treatment (p=0.87) 3 0.4 2 0.3 2 0.3 Delayed (p=0.0005) 21 3.0 5 0.7 6 0.9

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.841
Threshold uncertainty score0.316

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.163
GPT teacher head0.508
Teacher spread0.345 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer Treatment and PharmacologyFrench-language works237,207